Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension

Brain

Volumn 123, Issue 1, 2000, Pages 171-184

  Smith, Kenneth J ^a   Felts, Paul A ^a   John, Gareth R ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Demyelinating disease; Multiple sclerosis; Potassium channels; Spinal cord injury; Symptomatic therapy

Indexed keywords

4 AMINOPYRIDINE; ETHIDIUM BROMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEMYELINATION; DRUG MECHANISM; MALE; MUSCLE TONE; MUSCLE TWITCH; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD; SYNAPTIC TRANSMISSION; TEMPERATURE;

EID: 0033982291     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/123.1.171     Document Type: Article

References (69)

1. Agoston S, Bowman WC, Houwertjes MC, Rodger IW, Savage AO. Direct action of 4-aminopyridine on the contractility of a fast-contracting muscle in the cat. Clin Exp Pharmacol Physiol 1982; 9: 21-34.
2. Al-Zamil ZM, Bagust J, Kerkut GA. The effect of aminopyridines on the activity recorded in the dorsal roots of an isolated hamster spinal cord preparation. Gen Pharmacol 1988; 19: 189-93.
3. Ball AP, Hopkinson RB, Farrell ID, Hutchison JG, Paul R, Watson RD, et al. Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak. QJ Med 1979; 48: 473-91.
4. Bergin PS, Miller DH, Hirsch NP, Murray NM. Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol 1993; 34: 406-9.
5. Bever CT Jr. The current status of studies of aminopyridines in patients with multiple sclerosis. [Review]. Ann Neurol 1994; 36 Suppl: S118-21.
6. Bever CT Jr, Young D, Anderson PA, Krumhoiz A, Conway K, Leslie J, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994; 44: 1054-9.
7. Blakemore WF. Ethidium bromide induced demyelination in the spinal cord of the cat. Neuropathol Appl Neurobiol 1982; 8: 365-75.
8. Blight AR, Gruner JA. Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats. J Neurol Sci 1987; 82: 145-59.
9. Bo L, Dawson TM, Wesselingh S, Mork S, Choi S, Kong PA, et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994; 36: 778-86.
10. Bostock H, Sherratt RM, Sears TA. Overcoming conduction failure in demyelinated nerve fibres by prolonging action potentials. Nature 1978; 274: 385-7.
11. Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol (Lond) 1981; 313: 301-15.
12. Buckle PJ, Haas HL. Enhancement of synaptic transmission by 4-aminopyridine in hippocampal slices of the rat. J Physiol (Lond) 1982; 326: 109-22.
13. Chandy KG, DeCoursey TE, Cahalan MD, McLaughlin C, Gupta S. Voltage-gated potassium channels are required for human T lymphocyte activation. J Exp Med 1984; 160: 369-85.
14. Davis FA, Jacobson S. Altered thermal sensitivity in injured and demyelinated nerve. A possible model of temperature effects in multiple sclerosis. J Neurol Neurosurg Psychiatry 1971; 34: 551-61.
15. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990; 27: 186-92.
16. Davis FA, Stefoski D, Quandt FN. Mechanism of action of 4-aminopyridine in the symptomatic treatment of multiple sclerosis. Ann Neurol 1995; 37: 684.
17. DeCoursey TE, Chandy KG, Gupta S, Cahalan MD. Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis? Nature 1984; 307: 465-8.
18. Felts PA, Smith KJ. Conduction properties of central nerve fibers remyelinated by Schwann cells. Brain Res 1992; 574: 178-92.
19. Felts PA, Smith KJ. The use of potassium channel blocking agents in the therapy of demyelinating diseases. Ann Neurol 1994; 36: 454.
20. Felts PA, Smith KJ. Blood-brain barrier permeability in astrocyte-free regions of the central nervous system remyelinated by Schwann cells. Neuroscience 1996; 75: 643-55.
21. Galvan M, Grafe P, ten Bruggencate G. Convulsant actions of 4-aminopyridine on the guinea-pig olfactory cortex slice. Brain Res 1982; 241: 75-86.
22. Giovannoni G, Heales SJ, Silver NC, O'Riordan J, Miller RF, Land JM, et al. Raised serum nitrate and nitrite levels in patients with multiple sclerosis. J Neurol Sci 1997; 145: 77-81.
23. Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma 1993; 10: 1-18.
24. Hayes KC, Blight AR, Potter PJ, Allatt RD, Hsieh JT, Wolfe DL, et al. Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury. Paraplegia 1993; 31: 216-24.
25. Hayes KC, Potter PJ, Wolfe DL, Hsieh JT, Delaney GA, Blight AR. 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury. J Neurotrauma 1994; 11: 433-46.
26. Hirsh JK, Quandt FN. Aminopyridine block of potassium channels in mouse neuroblastoma cells. J Pharmacol Exp Ther 1993; 267: 604-11.
27. Jankowska E, Lundberg A, Rudomin P, Sykova E. Effects of 4-aminopyridine on transmission in excitatory and inhibitory synapses in the spinal cord. Brain Res 1977; 136: 387-92.
28. Jankowska E, Lundberg A, Rudomin P, Sykova E. Effects of 4-aminopyridine on synaptic transmission in the cat spinal cord. Brain Res 1982; 240: 117-29.
29. Johnson AW, Land JM, Thompson EJ, Bolanos JP, Clark JB, Heales SJ. Evidence for increased nitric oxide production in multiple sclerosis. J Neurol Neurosurg Psychiatry 1995; 58: 107.
30. Jonas P. Temperature dependence of gating current in myelinated nerve fibers. J Membr Biol 1989; 112: 277-89.
31. Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983; 60: 353-62.
32. Judge SIV, Yeh JZ, Mannie MD, Seifert LP, Paterson PY. Potassium channel blockers inhibit adoptive transfer of experimental allergic encephalomyelitis by myelin-basic-protein-stimulated rat T lymphocytes. J Biomed Sci 1997; 4: 169-78.
33. Kaji R, Sumner AJ. Effects of 4-aminopyridine in experimental CNS demyelination. Neurology 1988; 38: 1884-7.
34. Koo GC, Blake JT, Talento A, Nguyen M, Lin S, Sirotina A, et al. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol 1997; 158: 5120-8.
35. Lemeignan M, Millart H, Lamiable D, Molgo J, Lechat P. Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats. Brain Res 1984; 304: 166-9.
36. Lundh H. Effects of 4-aminopyridine on neuromuscular transmission. Brain Res 1978; 153: 307-18.
37. Lundh H, Nilsson O, Rosen I. 4-aminopyridine - a new drug tested in the treatment of Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry 1977; 40: 1109-12.
38. Lundh H, Nilsson O, Rosen I. Effects of 4-aminopyridine in myasthenia gravis. J Neurol Neurosurg Psychiatry 1979; 42: 171-5.
39. Matteson DR, Deutsch C. K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature 1984; 307: 468-71.
40. McDonald WI, Sears TA. The effects of experimental demyelination on conduction in the central nervous system. Brain 1970; 93: 583-98.
41. Molgo J, Lundh H, Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol 1980; 61: 25-34.
42. Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981; 31: 265-71.
43. Namerow NS. Circadian temperature rhythm and vision in multiple sclerosis. Neurology 1968; 18: 417-22.
44. Obaid AL, Salzberg BM. Micromolar 4-aminopyridine enhances invasion of a vertebrate neurosecretory terminal arborization: optical recording of action potential propagation using an ultrafast photodiode-MOSFET camera and a photodiode array. J Gen Physiol 1996; 107: 353-68.
45. Pineda J, Kogan JH, Aghajanian GK. Nitric oxide and carbon monoxide activate locus coeruleus neurons through a cGMP-dependent protein kinase: involvement of a nonselective cationic channel. J Neurosci 1996; 16: 1389-99.
46. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 1994a; 51: 292-6.
47. Polman CH, Bertelsmann FW, de Waal R, van Diemen HA, Uitdehaag BM, van Loenen AC, Koetsier JC. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 1994b; 51: 1136-9.
48. Potter PJ, Hayes KC, Hsieh JT, Delaney GA, Segal JL. Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases. Spinal Cord 1998; 36: 147-55.
49. Pratt K, Toombs JP, Widmer WR, Borgens RB. Plasma and cerebrospinal fluid concentrations of 4-aminopyridine following intravenous injection and metered intrathecal delivery in canines. J Neurotrauma 1995; 12: 23-39.
50. Rader RK, Kahn LE, Anderson GD, Martin CL, Chinn KS, Gregory SA. T cell activation is regulated by voltage-dependent and calcium-activated potassium channels. J Immunol 1996; 156: 1425-30.
51. Rasminsky M. The effects of temperature on conduction in demyelinated single nerve fibers. Arch Neurol 1973; 28: 287-92.
52. Russell JW, Windebank AJ, Harper CM Jr. Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine. Mayo Clinic Proc 1995; 70: 532-9.
53. Savage AO. A comparison of the effects of 4-dimethylaminopyridine and 4-aminopyridine on isolated cardiac and skeletal muscle preparations. Arch Int Pharmacodyn Ther 1985; 273: 262-76.
54. Sears TA, Bostock H. Conduction failure in demyelination: is it inevitable? Adv Neurol 1981; 31: 357-75.
55. Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980; 283: 570-2.
56. Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997; 77: 553-62.
57. Smith KJ. A sensitive method for the detection and quantification of conduction deficits in nerve. J Neurol Sci 1980; 48: 191-9.
58. Smith KJ. Conduction properties of central demyelinated and remyelinated axons, and their relation to symptom production in demyelinating disorders. EYE 1994; 8: 224-37.
59. Smith KJ, Hall SM. Nerve conduction during peripheral demyelination and remyelination. J Neurol Sci 1980; 48: 201-19.
60. Smith KJ, Schauf CL. Gallamine triethiodide (Flaxedil): tetraethylammonium- and pancuronium-like effects in myelinated nerve fibers. Science 1981; 212: 1170-2.
61. Smith EJ, Blakemore WF, McDonald WI. Central remyelination restores secure conduction. Nature 1979; 280: 395-6.
62. Spyker DA, Lynch C, Shabanowitz J, Sinn JA. Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol 1980; 16: 487-97.
63. Stefoski D, Davis FA, Faut M. Schauf CL. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987; 21: 71-77.
64. Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985; 328: 358-61.
65. Targ EF, Kocsis JD. Action potential characteristics of demyelinated rat sciatic nerve following application of 4-aminopyridine. Brain Res 1986; 363: 1-9.
66. van Diemen HA, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoorn MJ, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992; 32: 123-30.
67. van Diemen HA, Polman CH, van Dongen MM, Nauta JJ, Strijers RL, van Loenen AC, et al. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J Neurol Sci 1993; 116: 220-6.
68. van Ernst MG, Klis SF, Smoorenburg GF. 4-Aminopyridine effects on summating potentials in the guinea pig. Hear Res 1996; 102: 70-80.
69. Yun HY, Dawson VL, Dawson TM. Neurobiology of nitric oxide. Crit Rev Neurobiol 1996; 10: 291-316.